M-M-RVaxPro

RSS

measles, mumps and rubella vaccine (live)

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for M-M-RVaxPro. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use M-M-RVaxPro.

For practical information about using M-M-RVaxPro, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 04/04/2018

Authorisation details

Product details
Name
M-M-RVaxPro
Agency product number
EMEA/H/C/000604
Active substance
  • measles virus Enders’ Edmonston strain (live, attenuated)
  • mumps virus Jeryl Lynn (level B) strain (live, attenuated)
  • rubella virus Wistar RA 27/3 strain (live, attenuated)
International non-proprietary name (INN) or common name
measles, mumps and rubella vaccine (live)
Therapeutic area (MeSH)
  • Rubella
  • Mumps
  • Immunization
  • Measles
Anatomical therapeutic chemical (ATC) code
J07BD52
Publication details
Marketing-authorisation holder
MSD VACCINS
Revision
20
Date of issue of marketing authorisation valid throughout the European Union
04/05/2006
Contact address
162 avenue Jean Jaurès
69007 Lyon
France

Product information

19/02/2018 M-M-RVaxPro - EMEA/H/C/000604 - N/0087

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Vaccines

Therapeutic indication

M-M-RVaxPro is indicated for simultaneous vaccination against measles, mumps, and rubella in individuals 12 months or older.

For use in measles outbreaks, or for post-exposure vaccination, or for use in previously unvaccinated children older than 12 months who are in contact with susceptible pregnant women, and persons likely to be susceptible to mumps and rubella.

Assessment history

How useful was this page?

Add your rating